Articles tagged "B cells"

2020 American Transplant Congress
Recipient LAG3 Deficiency Results in Antibody-Mediated Rejection of Mouse Renal Allografts
M. Nicosia, R. Fan, J. Lee, V. Gorbacheva, A. Beavers, N. Dvorina, W. M. Baldwin III, R. L. Fairchild, B. Min, A. Valujskikh
Inflammation and Immunity, Cleveland Clinic, Cleveland, OH
*Purpose: Lymphocyte activation gene-3 (LAG3) is a coinhibitory receptor on the surface of T and B lymphocytes, NK cells and plasmacytoid dendritic cells. Its functions…
2020 American Transplant Congress
BAFF Inhibition to Prevent Antibody Rebound Following Proteasome Inhibitor-Based Desensitization: A Randomized, Controlled Trial
S. Tremblay¹, A. Rike-Shields², A. Govil¹, M. Cardi³, P. Brailey¹, R. Alloway¹, E. Woodle¹
¹U Cincinnati, Cincinnati, OH, ²Surgery, U Cincinnati, Christ Hospital, Cincinnati, OH, ³Christ Hospital, Cincinnati, OH
*Purpose: Proteasome inhibitor (PI) therapy reduces bone marrow plasma cells and HLA antibodies (Abs) in renal transplant candidates. However, rebound is common in many patients…
2020 American Transplant Congress
Immune Cell Subset Profiles in HLA-Sensitized Kidney Transplant Patients (HS KTx Pts) Desensitized with Clazakizumab (CLZ, Humanized Anti-IL-6 Monoclonal Antibody) Followed by Transplantation (Tx)
S. Ge¹, M. Chu¹, A. D. Guzman¹, E. D. Ortiz¹, A. Vo², N. Ammerman², S. C. Jordan², M. Toyoda¹
¹Transplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA, ²Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: IL-6, B cell growth factor, increases follicular T helper cell (Tfh) activity, promoting plasmablast (PB) and plasma cell (PC) differentiation, and antibody production. A…
2020 American Transplant Congress
Investigation of Il35 Expressing Regulatory B Cells in Tolerance of Kidney Transplantation
J. A. Sullivan, J. H. Fechner, E. Jankowska-Gan, W. J. Burlingham, D. B. Kaufman
Surgery, University of Wisconsin, Madison, WI
*Purpose: The development and maintenance of peripheral tolerance is required for long term success of solid organ transplantation without immuno-suppressive drugs. Using a novel, post-transplant,…
2020 American Transplant Congress
Evaluation of the Safety and Tolerability of Clazakizumab® as a Desensitization Agent in Highly-HLA Sensitized ESRD Patients (NCT03380962): 12m Follow-Up
A. A. Vo¹, N. Ammerman¹, E. Huang¹, M. Toyoda², S. Ge², A. Peng¹, R. Najjar¹, S. Williamson¹, C. Meyers¹, S. Sethi¹, K. Lim¹, J. Choi¹, S. C. Jordan¹
¹Kidney Transplant, Cedars Sinai Medical Ctr, Los Angeles, CA, ²Transplant Immunology Laboratory, Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: IL-6 mediates inflammation and activation of T-cells, B-cells & plasma cells. Thus, IL-6 may represent an important target for desensitization (DES). Here we report…
2020 American Transplant Congress
Bone Marrow Plasma Cell Heterogeneity Drives Resistance of Proteasome Inhibitor Therapy
C. M. Castro-Rojas¹, S. Tremblay², J. Driscoll³, K. Roskin⁴, R. R. Alloway³, E. Woodle², D. A. Hildeman¹
¹Immunobiology, Cincinnati Children's Hospital, Cincinnati, OH, ²Surgery, University of Cincinnati College of Medicine, Cincinnati, OH, ³Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, ⁴Biomedical Informatics, Cincinnati Children's Hospital, Cincinnati, OH
*Purpose: Patients sensitized to HLA antigens by prior transplantation, pregnancy or blood transfusion may have markedly prolonged waiting times for transplant. Moreover, once transplanted, the…
2020 American Transplant Congress
Dissecting Humoral Alloimmune Sensitization: A Dynamic Interplay of Different Cellular Compartments
A. Torija, A. Favà, E. Crespo, M. Jarque, M. Meneghini, N. Bolaños, J. Grinyo, O. Bestard
Kidney transplantation Unit, Bellvitge University Hospital- IDIBELL, L'Hospitalet de Llobregat. Barcelona, Spain
*Purpose: Humoral alloimmune memory is the main barrier for successful transplantation and is generated by a complex and compartmentalized B-cell immune response. Understanding the role…
2020 American Transplant Congress
Activated CD27⁺CD21^– Subset Dominate the Memory B Cell Response During Antibody-Mediated Rejection of Kidney Allografts
K. Louis¹, E. Bailly¹, C. Macedo¹, M. Marrari¹, M. Yamada¹, P. Randhawa¹, A. Zeevi¹, C. Lefaucheur², D. Metes¹
¹Surgery, University of Pittsburgh, Pittsburgh, PA, ²Inserm UMR 976, Paris, France
*Purpose: The role of alloreactive memory B (mB) cells in the pathogenesis of antibody-mediated rejection (ABMR) is increasingly recognized. Yet, a comprehensive characterization of mB…
2020 American Transplant Congress
Thymic B Cells: A Means to Control Regulatory Tolerance
C. LeGuern¹, S. Germana¹, N. Feeney¹, Z. Wang², N. Tanimine¹, C. Huang³, C. Rickert¹, J. Markmann¹
¹Surgery, Center for Transplantation Sciences, Massachusetts General Hospital, Charlestown, MA, ²University of Colorado Denver, Aurora, CO, ³Surgery, University of Colorado Denver, Aurora, CO
*Purpose: Therapies involving CD4 regulatory T cells (Tregs) are promising approaches to mitigate graft rejection and autoimmunity. Understanding of the activation mechanisms that initiate Treg…
2020 American Transplant Congress
Characterization of Non HLA Antibodies in Kidney Transplant Recipients
S. Rodriguez Ramirez¹, S. Clotet-Freixas¹, C. Mcevoy¹, M. Kotlyar², I. Jurisica², A. Chruscinski¹, A. Konvalinka³
¹Kidney Transplant, Toronto General Hospital Research Institute, Multi-Organ Transplant Program, University Health Network, Toronto, ON, Canada, ²Kidney Transplant, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ³Kidney Transplant, Department of Medicine, Division of Nephrology, University Health Network, Toronto, ON, Canada
*Purpose: Antibody mediated rejection (AMR) causes more than 60 percent of late graft failures in kidney transplants (KT). Although antiHLA donor specific antibodies are the…

« Previous Page
1
…
7
8
9
10
11
…
35
Next Page »